FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2054316063> ?p ?o ?g. }

• W2054316063 endingPage "320" @default.
• W2054316063 startingPage "314" @default.
• W2054316063 abstract "Resistin is a protein secreted from adipose tissue that is thought to play a role in insulin sensitivity. We examined the effects of rosiglitazone and metformin on the plasma resistin levels in individuals with type 2 diabetes mellitus. Patients with type 2 diabetes mellitus who showed poor glycemic control with glimepiride (4 mg/d) were randomized to rosiglitazone (4 mg/d) and metformin (500 mg bid) treatment groups. All subjects continued glimepiride treatment as well. The plasma concentrations of resistin were measured at baseline and at 6 months of treatment for both groups. The anthropometric parameters, fasting plasma glucose, HbA1c, total cholesterol, triglyceride, high-density lipoprotein cholesterol, free fatty acids, and adiponectin concentrations were also measured. After 6 months of treatment, the reduction in plasma glucose levels was similar between the 2 groups. There were no significant changes in the lipid profiles of either group during the study period. The plasma resistin levels decreased in the rosiglitazone group (2.49 ± 1.93 vs 1.95 ± 1.59 ng/ml; P < .05) but increased in the metformin group (2.61 ± 1.69 vs 5.13 ± 2.81 ng/ml; P < .05). The plasma adiponectin concentrations were increased in the rosiglitazone group (2.91 ± 1.46 vs 4.23 ± 1.77 μg/ml; P < .05) but were unchanged in the metformin group. In summary, rosiglitazone treatment decreased the plasma resistin levels whereas metformin treatment increased them in patients with type 2 diabetes mellitus showing poor glycemic control with sulfonylurea therapy. These results suggest that the observed changes in plasma resistin levels are not the consequences of improved insulin resistance, nor are they consequences of glycemic control. Considering the potential role of resistin in insulin resistance, decrease in resistin levels may contribute to improving insulin action with rosiglitazone treatment." @default.
• W2054316063 created "2016-06-24" @default.
• W2054316063 creator A5004961134 @default.
• W2054316063 creator A5008074124 @default.
• W2054316063 creator A5015507673 @default.
• W2054316063 creator A5017022880 @default.
• W2054316063 creator A5052740970 @default.
• W2054316063 creator A5055649755 @default.
• W2054316063 creator A5076948439 @default.
• W2054316063 creator A5087766825 @default.
• W2054316063 creator A5090460555 @default.
• W2054316063 date "2005-03-01" @default.
• W2054316063 modified "2023-10-15" @default.
• W2054316063 title "The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus" @default.
• W2054316063 cites W1675830194 @default.
• W2054316063 cites W1964233068 @default.
• W2054316063 cites W1973936104 @default.
• W2054316063 cites W1987328358 @default.
• W2054316063 cites W1991233000 @default.
• W2054316063 cites W2020949125 @default.
• W2054316063 cites W2027065577 @default.
• W2054316063 cites W2046503553 @default.
• W2054316063 cites W2049636225 @default.
• W2054316063 cites W2051820078 @default.
• W2054316063 cites W2071326073 @default.
• W2054316063 cites W2072676249 @default.
• W2054316063 cites W2072696561 @default.
• W2054316063 cites W2091220511 @default.
• W2054316063 cites W2091880327 @default.
• W2054316063 cites W2097794068 @default.
• W2054316063 cites W2107308458 @default.
• W2054316063 cites W2110678596 @default.
• W2054316063 cites W2114671731 @default.
• W2054316063 cites W2118991004 @default.
• W2054316063 cites W2121492052 @default.
• W2054316063 cites W2126241207 @default.
• W2054316063 cites W2127934772 @default.
• W2054316063 cites W2138226825 @default.
• W2054316063 cites W2139076623 @default.
• W2054316063 cites W2151954574 @default.
• W2054316063 cites W2157296874 @default.
• W2054316063 cites W2160234571 @default.
• W2054316063 cites W2161324995 @default.
• W2054316063 cites W2165139442 @default.
• W2054316063 cites W2165391345 @default.
• W2054316063 cites W2165708021 @default.
• W2054316063 cites W2166376415 @default.
• W2054316063 cites W2171152271 @default.
• W2054316063 doi "https://doi.org/10.1016/j.metabol.2004.05.019" @default.
• W2054316063 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15736108" @default.
• W2054316063 hasPublicationYear "2005" @default.
• W2054316063 type Work @default.
• W2054316063 sameAs 2054316063 @default.
• W2054316063 citedByCount "73" @default.
• W2054316063 countsByYear W20543160632012 @default.
• W2054316063 countsByYear W20543160632013 @default.
• W2054316063 countsByYear W20543160632014 @default.
• W2054316063 countsByYear W20543160632015 @default.
• W2054316063 countsByYear W20543160632017 @default.
• W2054316063 countsByYear W20543160632019 @default.
• W2054316063 countsByYear W20543160632021 @default.
• W2054316063 countsByYear W20543160632023 @default.
• W2054316063 crossrefType "journal-article" @default.
• W2054316063 hasAuthorship W2054316063A5004961134 @default.
• W2054316063 hasAuthorship W2054316063A5008074124 @default.
• W2054316063 hasAuthorship W2054316063A5015507673 @default.
• W2054316063 hasAuthorship W2054316063A5017022880 @default.
• W2054316063 hasAuthorship W2054316063A5052740970 @default.
• W2054316063 hasAuthorship W2054316063A5055649755 @default.
• W2054316063 hasAuthorship W2054316063A5076948439 @default.
• W2054316063 hasAuthorship W2054316063A5087766825 @default.
• W2054316063 hasAuthorship W2054316063A5090460555 @default.
• W2054316063 hasConcept C126322002 @default.
• W2054316063 hasConcept C134018914 @default.
• W2054316063 hasConcept C2776307423 @default.
• W2054316063 hasConcept C2776782570 @default.
• W2054316063 hasConcept C2777180221 @default.
• W2054316063 hasConcept C2777391703 @default.
• W2054316063 hasConcept C2778163477 @default.
• W2054316063 hasConcept C2778854520 @default.
• W2054316063 hasConcept C2778913445 @default.
• W2054316063 hasConcept C2779760629 @default.
• W2054316063 hasConcept C2780152017 @default.
• W2054316063 hasConcept C2780323712 @default.
• W2054316063 hasConcept C2780473172 @default.
• W2054316063 hasConcept C2910068830 @default.
• W2054316063 hasConcept C555293320 @default.
• W2054316063 hasConcept C71924100 @default.
• W2054316063 hasConceptScore W2054316063C126322002 @default.
• W2054316063 hasConceptScore W2054316063C134018914 @default.
• W2054316063 hasConceptScore W2054316063C2776307423 @default.
• W2054316063 hasConceptScore W2054316063C2776782570 @default.
• W2054316063 hasConceptScore W2054316063C2777180221 @default.
• W2054316063 hasConceptScore W2054316063C2777391703 @default.
• W2054316063 hasConceptScore W2054316063C2778163477 @default.
• W2054316063 hasConceptScore W2054316063C2778854520 @default.
• W2054316063 hasConceptScore W2054316063C2778913445 @default.
• W2054316063 hasConceptScore W2054316063C2779760629 @default.

• next